Fiore Healthcare Advisors

What Fiore Healthcare Advisors does

SSI Strategy LLC is a privately held biotech consulting and advisory firm headquartered in Morristown, New Jersey. The firm serves biotechnology companies across the full drug development lifecycle, from preclinical through commercialization, with a horizontal segmentation approach that spans early-stage biotechs through commercial-stage sponsors. Its service portfolio comprises ten core offerings: The Strategic Medical Office, Translational & Clinical Development, Clinical Operations, Evidence & Value, Medical Affairs, Program Management & Governance, Quality & Compliance, Regulatory Affairs, Safety & Pharmacovigilance, and High-Stakes Meetings. These services are delivered through senior-level engagements, with the firm positioning itself as a dedicated partner (Board Member, CEO, CMO, and Functional Leader roles) rather than a transactional service provider.

The firm's business model is professional-services-based, with quote-based pricing that is not publicly disclosed and revenue generated through direct enterprise engagement with biotech clients. Go-to-market relies on thought leadership across three podcast series (The Emerging Biotech Leader, The Emerging C-Suite Leader, and Build Talks), a five-part webinar series on the EU HTA Regulation, an Executive Advisory Network, and an NDA Advisory Board. The firm has developed specialized expertise around the EU HTA Regulation (Joint Clinical Assessment) and high-stakes FDA and EMA interactions, and in December 2025 it extended its quality and compliance capability through a partnership with Ready Room, an inspection-readiness platform.

In September 2025, SSI Strategy was acquired by Clinigen Group, transitioning ownership from an independent, founder- or management-controlled entity to a subsidiary of a larger strategic acquirer with global commercialization reach. The firm has no disclosed venture or private equity backing, no publicly disclosed revenue, and no disclosed headcount. Technology stack is not explicitly disclosed and no AI/ML capabilities are described in available sources.

Name

Fiore Healthcare Advisors

Legal name

SSI Strategy LLC

Website

https://fiorehealthcare.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

SSI Strategy is a privately held biotech consulting firm providing end-to-end drug development advisory services, from preclinical strategy through commercialization, to biotechnology companies via senior-led engagements and regulatory expertise.

Ownership category

akta.pro rank

Product category

Biotech Consulting & Drug Development Advisory

NAICS

Management, Scientific, and Technical Consulting Services (5416), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Management Consulting Services (8742), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

akta.pro secondary industries

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Medical Affairs, Scientific Communications & HEOR FSP (HLAGAOAG)

Keywords

• Biotech consulting services
• Clinical development advisory
• Regulatory affairs consulting
• Medical affairs strategy
• Drug development advisory

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Distribution channels1 record

Marketing channels6 records

Core offering

Fiore Healthcare Advisors provides multidisciplinary biotech consulting and advisory services spanning the drug development lifecycle, from preclinical through commercialization. Core offerings include The Strategic Medical Office, Translational & Clinical Development, Clinical Operations, Evidence & Value (with EU HTA Regulation/JCA guidance), Medical Affairs, Program Management & Governance, Quality & Compliance, Regulatory Affairs (including NDA Advisory Board), Safety & PV, and High-Stakes FDA/EMA Meetings, supported by an Executive Advisory Network.

Product overview

SSI Strategy is a consulting services company offering a comprehensive suite of biotech development support services organized as distinct professional service offerings. The portfolio includes nine core service lines covering the drug development lifecycle: The Strategic Medical Office, Translational & Clinical Development, Clinical Operations, Evidence & Value, Medical Affairs, Program Management & Governance, Quality & Compliance, Regulatory Affairs, Safety & PV, and High-Stakes Meetings. These services are complemented by thought leadership content (podcasts including The Emerging Biotech Leader and The Emerging C-Suite Leader, and Build Talks), an Executive Advisory Network, and an NDA Advisory Board. The company provides end-to-end support from pre-clinical stages through commercialization, guiding biotechs through FDA and EMA interactions. In December 2025, SSI Strategy announced a partnership with Ready Room to strengthen inspection readiness capabilities for biotech clients.

Differentiator

Problem solved

Functional benefit

Products and services

• The Strategic Medical Office Strategic medical leadership service ensuring scientific integrity and patient advocacy through strategic alignment and stakeholder engagement, designed for biotech sponsors seeking senior medical guidance.
• Translational & Clinical Development
• Clinical Operations
• Evidence & Value
• Medical Affairs
• Program Management & Governance
• Quality & Compliance
• Regulatory Affairs
• Safety & PV
• High-Stakes Meetings
• NDA Advisory Board
• Executive Advisory Network

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Clinigen GroupmajorStrategic or Co-development Partner · 29 September 2025Clinigen Group acquired SSI Strategy in September 2025. This acquisition enables SSI Strategy clients to access a seamless path from clinical strategy to global commercialization. The partnership strengthens the combined entity's ability to serve biotech innovators throughout the entire development lifecycle.

Scale indicators1 record

Recent moves1 record

Expansion highlights4 records

Direct peers

• Worldwide Clinical Trials: Mid-market CRO providing clinical operations, regulatory affairs, and pharmacovigilance services to biotech sponsors, with comparable therapeutic-area expertise and advisory-style engagement.
• Veristat: Biotech-focused clinical research and regulatory advisory firm offering biostatistics, regulatory strategy, and clinical operations — closely aligned with SSI Strategy's strategic advisory positioning.
• Medpace: Mid-sized clinical CRO with a strong biotech customer base offering full-service clinical operations and regulatory support, overlapping directly with SSI Strategy's clinical development and regulatory affairs offerings.
• Premier Research: Specialty CRO focused on emerging biotech and small to mid-sized biopharma, providing regulatory, clinical, and medical affairs services comparable to SSI Strategy's portfolio.
• Clinipace Worldwide: Mid-sized CRO serving emerging and mid-market biotech with regulatory, clinical, and biostatistics services, overlapping significantly with SSI Strategy's mid-stage biotech client segment.

Broad incumbents

• Parexel: Large global CRO offering regulatory strategy, clinical operations, and commercialization services across all phases — overlaps with SSI Strategy across multiple service lines but at enterprise scale.
• IQVIA: Largest global CRO and life sciences services provider, offering the full spectrum of regulatory, clinical, and commercialization services that overlap with SSI Strategy's offering but at vastly greater scale and breadth.
• Syneos Health: Biopharmaceutical services organization offering clinical development, regulatory, and commercial services with a biotech-heavy client base — comparable in customer overlap but broader in scale than SSI Strategy.
• ICON plc: Global CRO with comprehensive clinical, regulatory, and consulting capabilities serving biotech and large pharma — a broader-portfolio incumbent competitor to SSI Strategy's focused advisory offering.

Emerging players

• Cytel: Specialty biostatistics and evidence-generation firm serving biotech with regulatory and HTA-aligned analytics — a narrower competitor that overlaps with SSI Strategy's Evidence & Value service line and EU HTA specialization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/fiore-healthcare-advisors

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fiore Healthcare Advisors